Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zolpidem: distinct from triazolam?

B L Lobo1, W L Greene

  • 1Department of Pharmacy, Methodist Hospitals of Memphis-Central, TN 38104, USA.

The Annals of Pharmacotherapy
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Claims of equivalence in medical research: are they supported by the evidence?

Annals of internal medicine·2000
Same author

Symptomatic pharmacotherapy of migraine.

Clinical therapeutics·1999
Same author

Insomnia.

The New England journal of medicine·1997
Same author

A man with fever and petechiae.

Lancet (London, England)·1997
Same author

Fluconazole and amphotericin B for cryptococcal meningitis.

The Annals of pharmacotherapy·1996
Same author

ACCP Consensus Conference on Antithrombotic Therapy. Indicate specific low molecular weight heparin product and dosage.

Chest·1996
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
See all related articles

Zolpidem and triazolam show similar effects in humans, with no significant differences in efficacy or safety. This review found zolpidem offers no distinct therapeutic advantage over triazolam for insomnia treatment.

Area of Science:

  • Pharmacology
  • Clinical Medicine

Background:

  • Insomnia is a common sleep disorder.
  • Zolpidem and triazolam are commonly prescribed hypnotics.

Purpose of the Study:

  • To compare the efficacy and safety of zolpidem versus triazolam.
  • To review existing literature on these two insomnia medications.

Main Methods:

  • MEDLINE search (1983-1996) for English-language literature.
  • Inclusion of clinical trials comparing zolpidem and triazolam.
  • Evaluation of data on study design, efficacy, and adverse effects.

Main Results:

  • Zolpidem and triazolam exhibit similar pharmacokinetic and pharmacodynamic profiles.
  • Equipotent doses of both drugs showed no significant differences in efficacy, tolerability, residual effects, memory impairment, rebound insomnia, or abuse potential.

Related Experiment Videos

  • No significant differences in adverse effects were observed between zolpidem and triazolam.

    • Conclusions:

    • Zolpidem does not provide a clear therapeutic advantage over triazolam for treating insomnia.
    • Both medications appear comparable in their clinical profiles for insomnia management.